INDV

Indivior PLC · NASDAQ

Sector Health Technology
Industry Pharmaceuticals: Major
Website indivior.com
Employees(FY) 1000
ISIN GB00BN4HT335

Performance

+3.93%

+23.6%

-16.1%

-37.65%

-30.71%

YTD

-38.45%

Profile

Indivior PLC, together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and co-occurring disorders. The company's product pipeline focuses on treating opioid use disorder, addiction, and schizophrenia. It markets and promotes SUBLOCADE injection for subcutaneous use; and SUBOXONE sublingual film, SUBOXONE sublingual tablet, and SUBUTEX sublingual tablet. The company operates in approximately 40 countries worldwide. It has collaboration agreement with Addex Therapeutics Ltd. The company was incorporated in 2014 and is headquartered in North Chesterfield, Virginia.

Advanced Technical Analysis

Technical Analysis of INDV 2024-11-20

The stock exhibits a generally bullish sentiment with a Moving Average Score of 70 indicating strong upward momentum, while the Oscillators Score of 56 suggests a neutral stance that may require further confirmation. Overall, the combined Technical Score of 63 reinforces a positive outlook, signaling potential for continued strength in the stock...

Technical Scores and Rating

Moving Average Score

Oscillator Score

Technical Rating

Stock Analysis of INDV

Stock Rank

Recent News & Updates

2024-11-19 12:52
Rapid Initiation with Once-monthly SUBLOCADE® Superior to Standard Initiation for Treating Opioid Use Disorder, Including in Fentanyl-Positive Patients, According to Data Presented at CSAM 2024(PR Newswire)
2024-11-18 23:52
Rapid Initiation with Once-monthly SUBLOCADE Superior to Standard Initiation for Treating Opioid Use Disorder, Including in Fentanyl-Positive Patients, According to Data Presented at CSAM 2024(Prnewswire)
2024-11-07 14:24
Indivior Responds to Publication of a Letter by Oaktree Capital Management to the Board of Indivior(PR Newswire)
2024-11-07 01:24
Indivior Responds to Publication of a Letter by Oaktree Capital Management to the Board of Indivior(Prnewswire)
2024-10-30 12:30
Indivior Highlights Growing Body of Data on SUBLOCADE® (buprenorphine once-monthly extended-release injection) Helping Patients Achieve Long-Term Recovery from Opioid Use Disorder during Substance Abuse Prevention Month(PR Newswire)
2024-10-30 00:30
Indivior Highlights Growing Body of Data on SUBLOCADE (buprenorphine once-monthly extended-release injection) Helping Patients Achieve Long-Term Recovery from Opioid Use Disorder during Substance Abuse Prevention Month(Prnewswire)
2024-10-25 03:07
Indivior PLC (INDV) Q3 2024 Earnings Call Highlights: Strong Revenue Growth Amid Competitive ...(GuruFocus.com)
2024-10-24 07:05
Indivior PLC (INDV) Surpasses Q3 Earnings and Revenue Estimates(Zacks)
2024-10-24 02:00
Indivior Announces Q3 2024 Financial Results(PR Newswire)
2024-10-23 14:00
Indivior Announces Q3 2024 Financial Results(Prnewswire)
2024-10-22 21:09
Indivior PLC (INDV) Q3 2024 Earnings Report Preview: What to Expect(Yahoo Finance)
2024-10-17 17:03
Two Seas Capital LP Increases Stake in Indivior PLC(GuruFocus.com)
2024-10-12 08:35
Indivior price target lowered to $16 from $20 at Craig-Hallum(TipRanks)
2024-10-11 03:00
Indivior PLC (INDV) Q3 2024 Earnings Call Highlights: Navigating Competitive Pressures and ...(GuruFocus.com)
2024-10-10 09:08
Indivior Shares Fall Pre-Bell After Lowering Fiscal Year 2024 Revenue Outlook(MT Newswires)
2024-10-10 07:00
Indivior Provides Preliminary Q3 2024 Results; Updates FY 2024 Guidance; Group Continues to Expect SUBLOCADE Peak Net Revenue of >$1.5 Billion(PR Newswire)
2024-10-09 21:28
Indivior Cuts 2024 Outlook As Competition And Market Pressures Weigh On SUBLOCADE: Details(Yahoo Finance)
2024-10-09 19:00
Indivior Provides Preliminary Q3 2024 Results; Updates FY 2024 Guidance; Group Continues to Expect SUBLOCADE Peak Net Revenue of >$1.5 Billion(Prnewswire)
2024-10-07 12:38
Indivior Gets FDA Priority Review on Prior Approval Supplement for Sublocade(MT Newswires)
2024-10-07 11:30
Indivior's SUBLOCADE® Rapid Induction/Alternative Injection Site Prior Approval Supplement (PAS) Receives FDA Priority Review(PR Newswire)
2024-10-06 23:30
Indivior's SUBLOCADE Rapid Induction/Alternative Injection Site Prior Approval Supplement (PAS) Receives FDA Priority Review(Prnewswire)
2024-10-01 03:00
Addex Therapeutics Ltd (ADXN) Q2 2024 Earnings Call Transcript Highlights: Key Financials and ...(GuruFocus.com)
2024-09-25 04:34
Rigel (RIGL) Surges 19.7%: Is This an Indication of Further Gains?(Zacks)
2024-09-23 14:00
Top 3 Health Care Stocks That May Explode This Month(Benzinga)
2024-09-16 20:30
Indivior PLC Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - INDV(Prnewswire)
2024-09-12 17:45
Indivior PLC Sued for Securities Law Violations - Contact Levi & Korsinsky Before October 1, 2024 to Discuss Your Rights - INDV(Prnewswire)
2024-09-10 20:15
Indivior PLC Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - INDV(Prnewswire)
2024-09-05 17:45
Shareholders of Indivior PLC Should Contact Levi & Korsinsky Before October 1, 2024 to Discuss Your Rights - INDV(Prnewswire)
2024-09-04 02:00
Indivior Provides Update on Aelis Farma's Clinical Phase 2B Study Results with AEF0117 in Participants with Cannabis Use Disorder(PR Newswire)
2024-09-03 14:00
Indivior Provides Update on Aelis Farma's Clinical Phase 2B Study Results with AEF0117 in Participants with Cannabis Use Disorder(Prnewswire)

Page 1 of 4

previousnext

Disclaimer: The information provided here and on kavout.com site is for general informational purposes only. It does not constitute investment advice, financial advice, trading advice, or any other sort of advice. Kavout does not recommend that any investment decision be made based on this information. You are solely responsible for your own investment decisions. Please conduct your own research and consult with qualified financial advisors before making any investment. Kavout and its partners are participants in a number of affiliate advertising programs. As an Amazon Associate, Kavout or its partners earn from qualifying purchases from affiliate links. We also participate in other affiliate and advertising programs that provide a means for us to earn advertising fees by advertising and linking to third-party websites.